Glenmark Pharmaceuticals Limited share price
NSE: GLENMARK · ISIN INE935A01035
Key numbers
- Market cap
- ₹ 67,170 Cr
- Current price
- ₹ 2,380.00
- 52-week high / low
- ₹ 2,538 / 1,793
- Stock P/E
- 37.3
- Book value
- ₹ 372.5
- Dividend yield
- 0.32%
- ROCE
- 19.6%
- ROE
- 14.1%
- Debt to equity
- 0.06
- Sales growth (3 yrs)
- 13.5%
- Profit growth (3 yrs)
- 66.1%
- 1-year return
- 17.9%
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 3,059 | 6,004 | 3,888 | 3,760 | 3,932 |
| Operating profit | 581 | 2,360 | 870 | 763 | 805 |
| Net profit | 47 | 610 | 403 | 301 | 483 |
| EPS (₹) | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
Investor presentation summary (2026-07-31)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Consolidated Revenue of Rs. 40,185 million
- EBITDA at Rs. 8,048 million
Guidance & outlook
- of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”,
- Average conversion rate in 3M FY 2026-27 considered as INR 94.53 / USD 1.00
Growth & demand
- India business growth of 15.5%
- North America core business growth of 19.8%
Capex & expansion
- Expansion of the branded Dermatology
Balance sheet & cash
- profit, cash flows or financial performance based on applicable accounting standards.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.